Remoxy's "Complete Response" Letter Has No Clear Culprit But Many Suspects
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's abuse-deterrent, extended-release form of pain drug oxycodone faces legal, regulatory and manufacturing challenges.
You may also be interested in...
Deal Watch: Bristol Adds To Oncology Pipeline With F-star Alpha Option Pact
Novartis completes the divestiture of its vaccines business by selling off two influenza vaccines to Australia’s CSL Ltd. Zogenix buys out Britain’s Brabant pharma and Pain Therapeutics is searching for a new partner for Remoxy after Pfizer drops the abuse-deterrent opioid.
Remoxy Development Not ‘Unmitigated Disaster,’ CEO Reassures; Hunt Begins For New Partner
Pfizer terminates agreement with Pain Therapeutics after reviewing top-line results of five studies done to address FDA complete response letter; Pain says data supports refiling of NDA for its abuse-deterrent long-acting oxycodone formulation by mid-2015.
Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims
Abuse-deterrent opioids address a serious unmet need and help differentiate brands from the field of generics, but so far Purdue’s OxyContin remains the only opioid on the market with abuse-deterrent claims, even though FDA recently approved two new opioid analgesics.